NCT06113601

Brief Summary

Multicenter, observational and prospective study.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2024

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 11, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 2, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

November 2, 2023

Status Verified

October 1, 2023

Enrollment Period

6 months

First QC Date

July 11, 2023

Last Update Submit

November 1, 2023

Conditions

Hematological DiseasesCritical Illness

Outcome Measures

Primary Outcomes (1)

  • Hospital mortality.

    During the 6 months of the study.

Study Arms (2)

Patients admitted to the ICU.

Other: There is no intervention.

Patients who are not admitted to the ICU.

Other: There is no intervention.

Interventions

There is no intervention.OTHER

There is no intervention in the study.

Patients admitted to the ICU.Patients who are not admitted to the ICU.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a diagnosis of solid organ or hematological tumor who are admitted to the hospital and require ICU evaluation.

You may qualify if:

  • Adults
  • Solid organ tumor or hematological malignancy,

You may not qualify if:

  • under 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hematologic DiseasesCritical Illness

Condition Hierarchy (Ancestors)

Hemic and Lymphatic DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Elena Cuenca Fito

CONTACT

647113703ecuencafito@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 11, 2023

First Posted

November 2, 2023

Study Start

January 1, 2024

Primary Completion

July 1, 2024

Study Completion

September 1, 2024

Last Updated

November 2, 2023

Record last verified: 2023-10